Russell Basser Selected Research

CSL360

5/2015

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Russell Basser Research Topics

Disease

1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2015
1	Human Influenza (Influenza) 01/2010
1	Breast Neoplasms (Breast Cancer) 06/2007
1	Atherosclerotic Plaque (Atheroma) 04/2007
1	Coronary Artery Disease (Coronary Atherosclerosis) 04/2007
1	Hemorrhage 01/2002
1	Leukemia 01/2002
1	Thrombocytopenia (Thrombopenia) 01/2002

Drug/Important Bio-Agent (IBA)

1	CSL360IBA 05/2015
1	Monoclonal AntibodiesIBA 05/2015
1	AntigensIBA 01/2010
1	Hemagglutinins (Hemagglutinin)IBA 01/2010
1	VaccinesIBA 01/2010
1	CSL-111IBA 04/2007
1	HDL LipoproteinsIBA 04/2007
1	Interleukin-11 (Interleukin 11)IBA 01/2002
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2002
1	AntibodiesIBA 01/2002
1	Thrombopoietin (c-mpl Ligand)IBA 01/2002

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 06/2007 - 01/2002
1	Intramuscular Injections 01/2010
1	Autologous Transplantation 06/2007
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2002